Inovio Pharmaceuticals Statistics
Share Statistics
Inovio Pharmaceuticals has 26.10M shares outstanding. The number of shares has increased by -90.49% in one year.
| Shares Outstanding | 26.10M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 25.80M |
| Failed to Deliver (FTD) Shares | 21.45K |
| FTD / Avg. Volume | 5.54% |
Short Selling Information
The latest short interest is 3.50M, so 13.43% of the outstanding shares have been sold short.
| Short Interest | 3.50M |
| Short % of Shares Out | 13.43% |
| Short % of Float | 13.58% |
| Short Ratio (days to cover) | 11.22 |
Valuation Ratios
The PE ratio is -1 and the forward PE ratio is -1.39.
| PE Ratio | -1 |
| Forward PE | -1.39 |
| PS Ratio | 163.1 |
| Forward PS | 298.8 |
| PB Ratio | 1.16 |
| P/FCF Ratio | -1.09 |
| PEG Ratio | n/a |
Enterprise Valuation
Inovio Pharmaceuticals Inc. has an Enterprise Value (EV) of 151.60M.
| EV / Earnings | -1.12 |
| EV / Sales | 182.21 |
| EV / EBITDA | -1.16 |
| EV / EBIT | -1.12 |
| EV / FCF | -1.22 |
Financial Position
The company has a current ratio of 3.6, with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.6 |
| Quick Ratio | 3.6 |
| Debt / Equity | 0.14 |
| Total Debt / Capitalization | 12.5 |
| Cash Flow / Debt | -7.42 |
| Interest Coverage | -110.59 |
Financial Efficiency
Return on equity (ROE) is -1.15% and return on capital (ROIC) is -91.64%.
| Return on Equity (ROE) | -1.15% |
| Return on Assets (ROA) | -0.78% |
| Return on Capital (ROIC) | -91.64% |
| Revenue Per Employee | 6.55K |
| Profits Per Employee | -1.06M |
| Employee Count | 127 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -50.96% in the last 52 weeks. The beta is 0.83, so Inovio Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.83 |
| 52-Week Price Change | -50.96% |
| 50-Day Moving Average | 4.92 |
| 200-Day Moving Average | 8.37 |
| Relative Strength Index (RSI) | 14.49 |
| Average Volume (20 Days) | 387.23K |
Income Statement
In the last 12 months, Inovio Pharmaceuticals had revenue of $832.01K and earned -$135.12M in profits. Earnings per share was $-6.09.
| Revenue | 832.01K |
| Gross Profit | -2.67M |
| Operating Income | -135.23M |
| Net Income | -135.12M |
| EBITDA | -130.39M |
| EBIT | -135.23M |
| Earnings Per Share (EPS) | -6.09 |
Balance Sheet
The company has $14.31M in cash and $30.21M in debt, giving a net cash position of -$15.90M.
| Cash & Cash Equivalents | 14.31M |
| Total Debt | 30.21M |
| Net Cash | -15.90M |
| Retained Earnings | -1.62B |
| Total Assets | 107.06M |
| Working Capital | 67.79B |
Cash Flow
In the last 12 months, operating cash flow was -$124.37M and capital expenditures -$320.90K, giving a free cash flow of -$124.69M.
| Operating Cash Flow | -124.37M |
| Capital Expenditures | -320.90K |
| Free Cash Flow | -124.69M |
| FCF Per Share | -5.62 |
Margins
Gross margin is -321.09%, with operating and profit margins of -16.25K% and -16.24K%.
| Gross Margin | -321.09% |
| Operating Margin | -16.25K% |
| Pretax Margin | -16.24K% |
| Profit Margin | -16.24K% |
| EBITDA Margin | -15.67K% |
| EBIT Margin | -16.25K% |
| FCF Margin | -14.99K% |
Dividends & Yields
INO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -265.94% |
| FCF Yield | -208.62% |
Analyst Forecast
The average price target for INO is $12, which is 424% higher than the current price. The consensus rating is "Hold".
| Price Target | $12 |
| Price Target Difference | 424% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jan 25, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Jan 25, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | 735.71 |
| Piotroski F-Score | 1 |